<DOC>
	<DOCNO>NCT01958853</DOCNO>
	<brief_summary>The purpose open label study provide 24 active treatment noninvasive cortical electrostimulation therapy fibromyalgia patient experienced inadequate pain reduction sham control double blind lead study , NPT-201 ( NCT01825954 ) . The therapy provide NeuroPoint device use protocol use active treatment arm NPT-201 . The study 's primary outcome measure patient 's change baseline self-reported 24-hour average pain intensity . The study provide active treatment participant receive sham therapy NPT-201 , test whether additional therapy application might improve pain participant previously receive active therapy , achieve adequate pain relief .</brief_summary>
	<brief_title>Prospective Evaluation Reduced Impedance Noninvasive Cortical Electrostimulation ( RINCE ) Reduce Fibromyalgia Effects - Extension Study</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<criteria>Patient must successfully complete study NPT201 inadequate pain response , define &lt; 50 % reduction pain baseline participation NPT201 . Patient must provide write informed consent privacy authorization prior participation study . Female patient childbearing potential must willing use acceptable method birth control duration study participation . Acceptable birth control include vasectomized partner , contraceptive ( oral , parenteral , transdermal ) , intrauterine device , double barrier method include condom , sponge , diaphragm , vaginal ring spermicidal jelly cream . Patients consider childbearing potential must surgically sterile ( total hysterectomy , bilateral salpingooophorectomy , tubal ligation ) great one year postmenopausal , define complete cessation menstruation least one year . Patients must willing refrain exclude therapy duration study . In opinion Investigator , patient willing able comply protocolspecified requirement . Patient current significant psychological psychiatric disorder ( e.g. , severe , unstable poorly control depression , severe anxiety obsessivecompulsive disorder . Patient score 2 3 item 9 BDI , , base investigator 's judgment , patient risk suicidal ideation behavior . Patient resume treatment duloxetine , milnacipran , pregabalin , gabapentin , sodium oxybate prohibit narcotic . Female patient pregnant , plan pregnancy , breastfeed . Any anticipated need surgery might confound result interfere patient 's ability comply protocol . The occurrence major protocol violation leadin study indicate lack compliance significant concern preclude patient 's ongoing participation .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pain</keyword>
</DOC>